Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 2
2004 1
2005 7
2007 2
2008 9
2009 3
2010 1
2011 7
2012 3
2013 1
2014 4
2015 5
2016 4
2017 7
2018 10
2019 7
2020 6
2021 3
2022 7
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. Brown JWL, et al. Among authors: willis m. JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588. JAMA. 2019. PMID: 30644981 Free PMC article.
Alemtuzumab for Multiple Sclerosis.
Willis MD, Robertson NP. Willis MD, et al. Curr Neurol Neurosci Rep. 2016 Sep;16(9):84. doi: 10.1007/s11910-016-0685-y. Curr Neurol Neurosci Rep. 2016. PMID: 27485945 Free PMC article. Review.
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.
Zaloum SA, Wood CH, Tank P, Upcott M, Vickaryous N, Anderson V, Baker D, Chance R, Evangelou N, George K, Giovannoni G, Harding KE, Hibbert A, Ingram G, Jolles S, Kang AS, Loveless S, Moat SJ, Richards A, Robertson NP, Rios F, Schmierer K, Willis M, Dobson R, Tallantyre EC. Zaloum SA, et al. Among authors: willis m. Mult Scler. 2023 Jul;29(8):979-989. doi: 10.1177/13524585231185247. Mult Scler. 2023. PMID: 37431627 Free PMC article.
Clinical observation during alemtuzumab administration.
Allen CM, Feng JJ, Willis MD, McGinley M, Ontaneda D, Tallantyre EC, Evangelou N. Allen CM, et al. Among authors: willis md. Mult Scler Relat Disord. 2020 Jan;37:101412. doi: 10.1016/j.msard.2019.101412. Epub 2019 Sep 25. Mult Scler Relat Disord. 2020. PMID: 32172992 No abstract available.
COVID-19 Vaccine Response in People with Multiple Sclerosis.
Tallantyre EC, Vickaryous N, Anderson V, Asardag AN, Baker D, Bestwick J, Bramhall K, Chance R, Evangelou N, George K, Giovannoni G, Godkin A, Grant L, Harding KE, Hibbert A, Ingram G, Jones M, Kang AS, Loveless S, Moat SJ, Robertson NP, Schmierer K, Scurr MJ, Shah SN, Simmons J, Upcott M, Willis M, Jolles S, Dobson R. Tallantyre EC, et al. Among authors: willis m. Ann Neurol. 2022 Jan;91(1):89-100. doi: 10.1002/ana.26251. Epub 2021 Nov 17. Ann Neurol. 2022. PMID: 34687063 Free PMC article.
97 results